The definition of "AI-designed" is contested. Some outlets use the term loosely, and the FDA does not record how a drug was discovered, so the answer to whether AI has produced an approved drug depends on how the term is defined. Takeda's zasocitinib is computationally designed rather than AI-discovered in the strict sense. Insilico Medicine's rentosertib, which began a Phase III trial in mid-2026, is the most advanced candidate with a clearly AI-driven origin.
Investment is surging regardless. McKinsey data puts global venture and private equity investment in AI drug discovery at $8.4 billion in 2025, roughly double the level of two years earlier. The FDA and the European Medicines Agency published joint guiding principles for good AI practice in drug development on January 14, 2026. Attorneys advising on AI-related drug development, licensing, or investment should track the FDA's Priority Review of Takeda's zasocitinib, accepted September 14, 2026, with a target action date in the first quarter of 2027. Expect headlines to label an approval "AI-designed" even though the strict definition may not apply, so read the claims closely in any deal or regulatory filing.